Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis [version 1; referees: 1 approved, 2 approved with reservations]
Aim: Metastatic prostate cancer (mPCa) has a poor outcome with median survival of two to five years. The use of androgen deprivation therapy (ADT) is a gold standard in management of this stage. Aim of this study is to analyze the prognostic value of PSA kinetics of patient treated with hormonal th...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2018-02-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/7-246/v1 |